Omada Health’s Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

Rhea-AI Summary

Omada Health (OMDA) has released promising data demonstrating the effectiveness of their GLP-1 companion program in improving medication persistence and weight loss outcomes. The analysis of 1,124 members showed significantly higher persistence rates for GLP-1 medications - 94% through 12 weeks and 84% through 24 weeks, compared to previous real-world studies showing rates between 33-80%. Members who remained on their medication through 24 weeks achieved an average weight loss of 12.1%, compared to 7.4% for those who discontinued early. The program provides targeted support including dose titration guidance, side effect management, nutrition advice, and exercise specialist support. These results suggest Omada's enhanced care track can help patients achieve clinical trial-level outcomes in real-world settings, potentially leading to reduced cardiometabolic disease risk.

Positive

• High medication persistence rates achieved (94% at 12 weeks, 84% at 24 weeks) compared to previous studies (33-80%)
• Members who persisted with medication achieved 12.1% average weight loss at 24 weeks, matching clinical trial outcomes
• Program demonstrates 64% better weight loss results for persistent users vs non-persistent users
• Company has established credibility with over a decade of data and 29 peer-reviewed publications

Negative

• Members who discontinued medication early only achieved 7.4% average weight loss
• Program success heavily dependent on medication adherence
• Results based on self-reported GLP-1 use, though verified with pharmacy claims data

Insights

Healthcare Industry Analyst

Omada's GLP-1 program shows 84% medication persistence at 24 weeks, yielding clinical-trial level weight loss of 12.1%.

This new data from Omada Health represents a significant advancement in addressing one of the primary challenges with GLP-1 medications: real-world persistence. The analysis of 1,124 non-diabetic members reveals persistence rates of 94% through 12 weeks and 84% through 24 weeks – substantially higher than previous real-world studies showing rates as low as 42% at 12 weeks and 33% at 24 weeks.

The clinical implications are substantial. Members who remained on their GLP-1 medication for 24 weeks achieved an average weight loss of 12.1%, compared to just 7.4% for those who discontinued – representing a 64% relative improvement. Most notably, these results align with outcomes from head-to-head clinical trials of tirzepatide and semaglutide, suggesting Omada's program can help bridge the gap between controlled research settings and real-world implementation.

Omada's approach targets specific barriers to medication persistence through high-touch interventions: dose titration support, side effect management strategies, nutrition guidance, and exercise specialist involvement to prevent muscle loss. The program also addresses medication access challenges – a critical factor given the high demand and cost barriers associated with these medications.

The timing of this data release is strategically significant as GLP-1 access continues to expand. By demonstrating improved persistence and consequently better outcomes, Omada positions itself as an essential complement to medication therapy rather than just another digital health offering. For payers and employers increasingly covering these expensive medications, Omada's program potentially represents a value-multiplier by ensuring the substantial investment in GLP-1s translates to meaningful clinical outcomes.

New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises

SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data¹ demonstrating that Omada’s GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.² Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.¹

Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,³ while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in the first month, and less than half stayed on for more than 12 weeks.⁴ These data suggest that in the real world, factors like non-persistent medication use mean that many who use GLP-1s for weight management may not see the results reflected in clinical trials.

“While published literature illustrates the incredible potential of GLP-1s, these outcomes are generally limited to those who consistently use their medication long enough to see benefit. In the real world many patients do not receive the necessary support for this to be a reality,” said Sarah Linke, PhD, MPH, Senior Director, Clinical & Translational Research, Omada Health. “Omada's GLP-1 companion program helps individuals maintain their medication regimen and, in this analysis, helped members achieve clinical trial-level outcomes in real-world settings, which sets the stage for cardiometabolic disease reduction.”

Omada analyzed 1,124 members without diabetes who self-reported GLP-1 use to assess the impact of its Enhanced GLP-1 Care Track on medication persistence through 24 weeks. Self-reported medication initiation and persistence were confirmed using objective pharmacy claims data. Previous real-world studies have demonstrated a wide range in medication persistence rates at 12 weeks (42%⁴ to 80%⁵) and 24 weeks (33%⁶ to 74%⁵) after starting GLP-1s. In contrast, members included in this analysis of Omada’s Enhanced GLP-1 Care Track demonstrated higher persistence rates—94% through 12 weeks and 84% through 24 weeks.¹

This analysis also found the average weight loss for Omada members that persisted on their medication through 24 weeks was closely aligned with 24-week outcomes from a recent head-to-head clinical trial⁷ comparing tirzepatide and semaglutide in a similar population. Whereas Omada members who stopped taking their GLP-1 medication any time before 24 weeks lost an average of 7.4% of their body weight, those who remained on their medication through 24 weeks lost an average of 12.1%—a 64% relative increase.¹ Providing the right kind of support to enable members to persist with their GLP-1 medication long enough to see benefits can help them achieve clinical trial-level weight loss outcomes, setting the stage for cardiometabolic disease risk reduction.

Omada’s Enhanced GLP-1 Care Track provides targeted resources for members as they move through their GLP-1 use journey. Members in this companion program receive high-touch care team support to help overcome common barriers to persistence – from education around dose titration, common side effects, and mitigation strategies to nutrition guidance and support from Exercise Specialists to combat muscle loss. Members who plan to stop their medication due to access concerns may receive resources that help them understand their options and navigate the larger healthcare ecosystem.

“We are in the fortunate position that more patients are getting access to these transformative medications,” said Wei-Li Shao, President, Omada Health. “However, with increased access comes the responsibility to ensure GLP-1 use remains cost-effective by supporting sustainable long-term health benefits. We believe these findings highlight the potential of Omada’s program to enhance clinical outcomes with improved medication persistence and a focus on engagement in healthy lifestyle behavior changes."

This analysis was conducted through Omada’s Insights Lab as part of the ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) initiative, and builds on more than a decade of insights and 29 peer-reviewed publications assessing the efficacy of behavior change programs to improve chronic disease management.

Omada Health
Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 29 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada’s scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s.

The foundation of Omada’s success is a strong, vibrant work culture, which helped earn the company the distinction of becoming an officially certified Great Place to Work^®. An industry leader, Omada was the first virtual provider to join the Institute for Healthcare Improvement’s Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently.

Contacts
Rose Ramseth
press@omadahealth.com

¹Chang, H., Devaraj, S. M., Naqvi, J. B., & Linke, S. (2025). GLP-1 Medication Persistence, a Key Component of Weight Loss. Omada Health. GLP-1 Medication Persistence, a Key Component of Weight Loss. Omada Health. https://resourcecenter.omadahealth.com/white-papers/glp-1-medication-persistence-a-key-component-of-weight-loss
²Gasoyan, H., Butsch, W. S., Schulte, R., Casacchia, N. J., Le, P., Boyer, C. B., Griebeler, M. L., Burguera, B., & Rothberg, M. B. (2025). Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity, 2025, 1-11. https://doi.org/10.1002/oby.24331
³Xie, Y., Choi, T., & Al-Aly, Z. (2025). Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature, 31, 951–962. https://doi.org/10.1038/s41591-024-03412-w
⁴Blue Health Intelligence^®. (2024, May). Real‑world trends in GLP‑1 treatment persistence and prescribing for weight management [PDF]. Blue Cross Blue Shield Association. Retrieved June 16, 2025, from https://www.bcbs.com/dA/46383dfc2d/fileAsset/BHI_Issue_Brief_GLP1_Trends.pdf
⁵Hankosky, E. R., Karishma, D., Chinthammit, C., Grabner, M., Stockbower, G., He, X., Mojdami, D., Wenziger, C., & Gibble, T. H. (2025). Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States. Diabetes & Metabolism, 51 (3), 101636. https://doi.org/10.1016/j.diabet.2025.101636
⁶Gleason, P. P., Urick, B. Y.,Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024). Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. Journal of Managed Care & Specialty Pharmacy, 30 (8), 860-867. https://doi.org/10.18553/jmcp.2024.23332
⁷Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Valderas, E. G., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, NEJM, 2025. https://doi.org/10.1056/NEJMoa2416394

FAQ

What are the persistence rates for Omada Health's GLP-1 program at 12 and 24 weeks?

Omada's program achieved 94% persistence through 12 weeks and 84% through 24 weeks, significantly higher than previous real-world studies showing rates between 33-80%.

How much weight loss did OMDA members achieve with the GLP-1 program?

Members who persisted with medication for 24 weeks lost an average of 12.1% body weight, while those who discontinued early lost 7.4% on average.

What support does Omada's Enhanced GLP-1 Care Track provide?

The program provides dose titration guidance, side effect management strategies, nutrition guidance, exercise specialist support, and resources for medication access concerns.

How many members were included in Omada's GLP-1 analysis?

The analysis included 1,124 members without diabetes who self-reported GLP-1 use, with medication use verified through pharmacy claims data.

What makes Omada's GLP-1 program different from standard care?

Omada's program offers high-touch care team support, targeted resources throughout the medication journey, and comprehensive lifestyle modification guidance to improve medication persistence and outcomes.